SYMTUZA® Clinical Trial & Safety Info
Study design, efficacy, safety
Study design, efficacy, safety
Study design, efficacy, safety
Molecular properties of darunavir, the only single-tablet regimen with the protective barrier of darunavir
The protective barrier to resistance of darunavir in a convenient STR. Includes dosing and drug interaction information
*DIAMOND was not a pivotal registration trial.
STR=single-tablet regimen
References: 1. SYMTUZA® Prescribing Information. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP. 2. Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir